⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for selinexor

Every month we try and update this database with for selinexor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple MyelomaNCT03850704
Multiple Myelom...
Selinexor
18 Years - Masonic Cancer Center, University of Minnesota
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT02299518
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Recurrent Adult...
Secondary Acute...
mitoxantrone hy...
etoposide
cytarabine
selinexor
laboratory biom...
pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaNCT05786989
Diffuse Large B...
selinexor
18 Years - 75 YearsChongqing University Cancer Hospital
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic CancerNCT02178436
Acinar Cell Ade...
Duct Cell Adeno...
Stage IV Pancre...
gemcitabine hyd...
Selinexor
Pharmacological...
Laboratory Biom...
Nab paclitaxel
19 Years - Barbara Ann Karmanos Cancer Institute
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic SyndromeNCT02212561
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Mixed Phenotype...
Selinexor
Fludarabine
Cytarabine
methotrexate/hy...
- 24 YearsSt. Jude Children's Research Hospital
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaNCT04898894
Acute Leukemia ...
Acute Myeloid L...
Refractory Acut...
Refractory Acut...
Venetoclax
Selinexor
Cytarabine
Fludarabine
Filgrastim
Methotrexate
methotrexate/hy...
2 Years - 30 YearsSt. Jude Children's Research Hospital
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and OsteosarcomaNCT04595994
Sarcoma,Soft Ti...
Selinexor
18 Years - 80 YearsGrupo Espanol de Investigacion en Sarcomas
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaNCT05736965
AML, Adult
Selinexor
Azacitidine
Venetoclax
18 Years - Shanghai Tong Ren Hospital
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentNCT05432804
MGMT-Methylated...
Recurrent Gliob...
Recurrent MGMT-...
Biospecimen Col...
Magnetic Resona...
Selinexor
Temozolomide
18 Years - National Cancer Institute (NCI)
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)NCT03095612
Non-small Cell ...
Selinexor
Docetaxel
18 Years - University of Texas Southwestern Medical Center
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881
Locally Advance...
Selinexor
Pembrolizumab
18 Years - Karyopharm Therapeutics Inc
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor CancerNCT01607905
Solid Tumor
Selinexor
Acetaminophen
18 Years - Karyopharm Therapeutics Inc
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaNCT04421378
Glioblastoma Mu...
Selinexor
Temozolomide (T...
Lomustine (CCNU...
Standard Fracti...
Bevacizumab
TTField
Carmustine
18 Years - Karyopharm Therapeutics Inc
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MMNCT04414475
Multiple Myelom...
Selinexor
Dexamethasone
Bortezomib
Pomalidomide
18 Years - Karyopharm Therapeutics Inc
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)NCT02146833
Prostate Cancer
Selinexor
18 Years - Karyopharm Therapeutics Inc
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495
Advanced Malign...
Clinical Stage ...
Clinical Stage ...
Fallopian Tube ...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Rena...
Ovarian Carcino...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Primary Periton...
Stage III Lung ...
Stage III Renal...
Stage IIIA Lung...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Lung ...
Stage IVB Lung ...
Triple-Negative...
Unresectable Lu...
Unresectable Me...
Unresectable Re...
Capecitabine
Carboplatin
Cyclophosphamid...
Doxorubicin
Eribulin
Fluorouracil
Ipilimumab
Irinotecan Hydr...
Leucovorin Calc...
Nivolumab
Olaparib
Oxaliplatin
Paclitaxel
Pembrolizumab
Pemetrexed
Selinexor
Topotecan
18 Years - M.D. Anderson Cancer Center
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MMNCT04414475
Multiple Myelom...
Selinexor
Dexamethasone
Bortezomib
Pomalidomide
18 Years - Karyopharm Therapeutics Inc
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MMNCT04414475
Multiple Myelom...
Selinexor
Dexamethasone
Bortezomib
Pomalidomide
18 Years - Karyopharm Therapeutics Inc
Selinexor, Cyclophosphamide and Prednisone in MyelomaNCT06212596
Relapsed or Ref...
Selinexor
Cyclophosphamid...
Prednisone
18 Years - University of Leeds
Selinexor in Treating Patients With Relapsed Small Cell Lung CancerNCT02351505
Recurrent Small...
Selinexor
Laboratory Biom...
Pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsNCT05985161
Wilms Tumor
Rhabdoid Tumor
Malignant Perip...
MPNST
Nephroblastoma
XPO1 Gene Mutat...
Solid Tumor
Selinexor
12 Months - Memorial Sloan Kettering Cancer Center
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaNCT04661137
Multiple Myelom...
Selinexor 60 MG
Selinexor 80 MG
Selinexor 100 M...
Carfilzomib
Pomalidomide
Daratumumab
Dexamethasone
18 Years - Hackensack Meridian Health
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLNCT03661515
Acute Myeloid L...
Selinexor
fludarabine
idarubicin
cytarabine
G-CSF
18 Years - 65 YearsPETHEMA Foundation
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.NCT04519476
Refractory Mult...
Selinexor
Lenalidomide
Methylprednisol...
18 Years - Oncotherapeutics
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaNCT05597345
Smoldering Mult...
Selinexor
18 Years - University of Rochester
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialNCT04764942
Recurrent Multi...
Refractory Mult...
Carfilzomib
Dexamethasone
Pomalidomide
Quality-of-Life...
Questionnaire A...
Selinexor
X-Ray Imaging
Computed Tomogr...
Positron Emissi...
Bone Marrow Bio...
Bone Marrow Asp...
Biospecimen Col...
18 Years - Mayo Clinic
Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom StudyNCT05333458
Advanced Alveol...
Advanced Soft T...
Metastatic Alve...
Unresectable Al...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Magnetic Resona...
Selinexor
18 Years - National Cancer Institute (NCI)
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade GliomasNCT02323880
Malignant Gliom...
Recurrent Brain...
Recurrent Child...
Recurrent Child...
Recurrent Lymph...
Recurrent Malig...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
WHO Grade 3 Gli...
Pharmacological...
Selinexor
12 Months - 21 YearsChildren's Oncology Group
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After TransplantNCT02485535
Acute Myeloid L...
de Novo Myelody...
Myelodysplastic...
Secondary Acute...
Secondary Myelo...
Laboratory Biom...
Selinexor
- University of Chicago
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422
Endometrial Can...
Selinexor
Matching placeb...
18 Years - Karyopharm Therapeutics Inc
A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsNCT05985161
Wilms Tumor
Rhabdoid Tumor
Malignant Perip...
MPNST
Nephroblastoma
XPO1 Gene Mutat...
Solid Tumor
Selinexor
12 Months - Memorial Sloan Kettering Cancer Center
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422
Endometrial Can...
Selinexor
Matching placeb...
18 Years - Karyopharm Therapeutics Inc
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaNCT04640779
Recurrent Histi...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Plasm...
Refractory Hist...
Refractory Hodg...
Refractory Non-...
Refractory Plas...
Choline Salicyl...
Selinexor
18 Years - Mayo Clinic
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaNCT04856189
Advanced Urothe...
Locally Advance...
Metastatic Urot...
Refractory Urot...
Pembrolizumab
Selinexor
18 Years - University of California, Davis
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal CancerNCT02384850
Colorectal Neop...
Selinexor
Oxaliplatin
5-FU
Folinic Acid
18 Years - GSO Global Clinical Research BV
A Study of Different Dosing Schedules of Selinexor in Sarcoma PatientsNCT04811196
Soft Tissue Sar...
Malignant Perip...
Leiomyosarcoma
Endometrial Str...
Selinexor
18 Years - University Health Network, Toronto
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal CancerNCT02384850
Colorectal Neop...
Selinexor
Oxaliplatin
5-FU
Folinic Acid
18 Years - GSO Global Clinical Research BV
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma - SEATTLE-NCT05954780
Multiple Myelom...
Selinexor
18 Years - iOMEDICO AG
Selinexor in Combination With Ixazomib for the Treatment of Advanced SarcomaNCT03880123
Liposarcoma
Malignant Perip...
Alveolar Soft P...
Ewing Sarcoma
Sarcoma
Selinexor
Ixazomib
14 Years - Columbia University
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaNCT04216329
Gliosarcoma
Newly Diagnosed
Glioblastoma
Selinexor
Temozolomide
Generic Radiati...
18 Years - National Institutes of Health Clinical Center (CC)
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia PatientsNCT02835222
Untreated Adult...
Cytarabine
Daunorubicin Hy...
Selinexor
18 Years - Wake Forest University Health Sciences
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaNCT04216329
Gliosarcoma
Newly Diagnosed
Glioblastoma
Selinexor
Temozolomide
Generic Radiati...
18 Years - National Institutes of Health Clinical Center (CC)
A Study of Different Dosing Schedules of Selinexor in Sarcoma PatientsNCT04811196
Soft Tissue Sar...
Malignant Perip...
Leiomyosarcoma
Endometrial Str...
Selinexor
18 Years - University Health Network, Toronto
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDPNCT02741388
B-cell Lymphoma
selinexor
Rituximab
Dexamethasone
Oxaliplatin
Cisplatin
Cytarabine
Gemcitabine
18 Years - 70 YearsThe Lymphoma Academic Research Organisation
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia PatientsNCT02835222
Untreated Adult...
Cytarabine
Daunorubicin Hy...
Selinexor
18 Years - Wake Forest University Health Sciences
Selinexor in Combination With Ixazomib for the Treatment of Advanced SarcomaNCT03880123
Liposarcoma
Malignant Perip...
Alveolar Soft P...
Ewing Sarcoma
Sarcoma
Selinexor
Ixazomib
14 Years - Columbia University
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLNCT02403310
Leukemia
Acute Myeloid L...
AML
Selinexor
Daunorubicin
Cytarabine
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate CancerNCT02215161
Castration Leve...
Hormone-Resista...
Metastatic Pros...
Prostate Carcin...
PSA Progression
Stage IV Prosta...
Selinexor
18 Years - University of California, San Francisco
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentNCT05432804
MGMT-Methylated...
Recurrent Gliob...
Recurrent MGMT-...
Biospecimen Col...
Magnetic Resona...
Selinexor
Temozolomide
18 Years - National Cancer Institute (NCI)
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06158841
Multiple Myelom...
ABBV-383
Carfilzomib
Pomalidomide
Elotuzumab
Selinexor
Bortezomib
Dexamethasone
18 Years - AbbVie
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaNCT04756401
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Daratumumab
Dexamethasone
Quality-of-Life...
Selinexor
18 Years - Academic and Community Cancer Research United
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple MyelomaNCT02780609
Multiple Myelom...
Selinexor
Melphalan
Dexamethasone
Autologous Hema...
Fosaprepitant
18 Years - H. Lee Moffitt Cancer Center and Research Institute
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseNCT05900882
Multiple Myelom...
Selinexor
Bortezomib
Lenalidomide
Dexamethasone
18 Years - 75 YearsThe First Affiliated Hospital with Nanjing Medical University
Selinexor Combination Ph 1 StudyNCT05177276
Solid Tumor Mal...
Selinexor
Irinotecan
18 Years - Hackensack Meridian Health
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal CancerNCT02137356
Rectal Neoplasm...
standard dose p...
standard dose c...
dose-escalated ...
18 Years - Sheba Medical Center
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaNCT02628704
Multiple Myelom...
Selinexor
Placebo (for se...
carfilzomib
Dexamethasone
18 Years - Karyopharm Therapeutics Inc
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaNCT02416908
Acute Myeloid L...
Selinexor
Cladribine
G-CSF
Cytarabine
Bone marrow bio...
18 Years - 70 YearsWashington University School of Medicine
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentNCT05432804
MGMT-Methylated...
Recurrent Gliob...
Recurrent MGMT-...
Biospecimen Col...
Magnetic Resona...
Selinexor
Temozolomide
18 Years - National Cancer Institute (NCI)
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsNCT04843579
Myeloma Multipl...
Myeloma
Refractory Mult...
Selinexor
Clarithromycin
Pomalidomide
Dexamethasone
18 Years - 74 YearsWeill Medical College of Cornell University
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological CancerNCT01607892
Hematological M...
KPT-330
18 Years - Karyopharm Therapeutics Inc
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaNCT03589222
Refractory Mult...
Selinexor
Daratumumab
Bortezomib
Dexamethasone
18 Years - PETHEMA Foundation
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422
Endometrial Can...
Selinexor
Matching placeb...
18 Years - Karyopharm Therapeutics Inc
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)NCT04607772
Relapsed or Ref...
Selinexor
Rituximab
Bendamustine
Polatuzumab Ved...
Ibrutinib
Lenalidomide
Tafasitamab
Venetoclax
Gemcitabine
Oxaliplatin
18 Years - Karyopharm Therapeutics Inc
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialNCT04764942
Recurrent Multi...
Refractory Mult...
Carfilzomib
Dexamethasone
Pomalidomide
Quality-of-Life...
Questionnaire A...
Selinexor
X-Ray Imaging
Computed Tomogr...
Positron Emissi...
Bone Marrow Bio...
Bone Marrow Asp...
Biospecimen Col...
18 Years - Mayo Clinic
Selinexor in Patients With Advanced Thymoma and Thymic CarcinomaNCT03466827
Thymoma
Advanced Thymic...
Selinexor
18 Years - Rigshospitalet, Denmark
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaNCT05786989
Diffuse Large B...
selinexor
18 Years - 75 YearsChongqing University Cancer Hospital
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaNCT04856189
Advanced Urothe...
Locally Advance...
Metastatic Urot...
Refractory Urot...
Pembrolizumab
Selinexor
18 Years - University of California, Davis
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)NCT06239272
Non-rhabdomyosa...
Adipocytic Neop...
Liposarcoma
Surgical resect...
Proton beam rad...
Pazopanib
Ifosfamide
Doxorubicin
Selinexor
- 30 YearsSt. Jude Children's Research Hospital
Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary ChemotherapyNCT03193437
Thymoma
Advanced Thymic...
Open Label Seli...
18 Years - Georgetown University
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome PatientsNCT02431351
Myelodysplastic...
Selinexor
18 Years - Karyopharm Therapeutics Inc
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid LeukemiaNCT03071276
Acute Myeloid L...
Selinexor
Fludarabine
Cytarabine
methotrexate/hy...
- 24 YearsSt. Jude Children's Research Hospital
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaNCT02436707
Lymphoma
Ibrutinib
Rituximab
Gemcitabine
Dexamethasone
Cisplatin
Mesna
Cyclophosphamid...
Etoposide
G-CSF
Selinexor
16 Years - 65 YearsCanadian Cancer Trials Group
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological CancerNCT01607892
Hematological M...
KPT-330
18 Years - Karyopharm Therapeutics Inc
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell LymphomaNCT03212937
Peripheral T-ce...
Selinexor
ICE Chemotherap...
18 Years - 90 YearsNational Cancer Centre, Singapore
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562
Multiple Myelom...
Selinexor
Bortezomib
Dexamethasone
18 Years - Karyopharm Therapeutics Inc
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaNCT06169215
Multiple Myelom...
Biospecimen Col...
Bone Marrow Bio...
Bortezomib
Computed Tomogr...
Daratumumab
Daratumumab and...
Dexamethasone
Lenalidomide
Magnetic Resona...
Positron Emissi...
Selinexor
- National Cancer Institute (NCI)
A Trial of Selinexor, Ruxolitinib and MethylprednisoloneNCT06225310
Multiple Myelom...
Multiple Myelom...
Selinexor
Ruxolitinib
Methylprednisol...
- Oncotherapeutics
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaNCT02628704
Multiple Myelom...
Selinexor
Placebo (for se...
carfilzomib
Dexamethasone
18 Years - Karyopharm Therapeutics Inc
Selinexor, Cyclophosphamide and Prednisone in MyelomaNCT06212596
Relapsed or Ref...
Selinexor
Cyclophosphamid...
Prednisone
18 Years - University of Leeds
Selinexor Treatment of Refractory MyelomaNCT02336815
Multiple Myelom...
Selinexor
Dexamethasone
18 Years - Karyopharm Therapeutics Inc
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: